JP5808536B2 - 抗ｒｓｖｇタンパク質抗体 - Google Patents

抗ｒｓｖｇタンパク質抗体 Download PDF

Info

Publication number
JP5808536B2
JP5808536B2 JP2010531283A JP2010531283A JP5808536B2 JP 5808536 B2 JP5808536 B2 JP 5808536B2 JP 2010531283 A JP2010531283 A JP 2010531283A JP 2010531283 A JP2010531283 A JP 2010531283A JP 5808536 B2 JP5808536 B2 JP 5808536B2
Authority
JP
Japan
Prior art keywords
seq
positions
rsv
region
antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2010531283A
Other languages
English (en)
Japanese (ja)
Other versions
JP2011500091A5 (https=
JP2011500091A (ja
Inventor
カウバー、ローレンス、エム．
コラリーニ、エレン、ジェイ．
キート、ブルース
フォード、オリット
Original Assignee
トレリス バイオサイエンス、インク．
トレリス バイオサイエンス、インク．
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by トレリス バイオサイエンス、インク．, トレリス バイオサイエンス、インク． filed Critical トレリス バイオサイエンス、インク．
Publication of JP2011500091A publication Critical patent/JP2011500091A/ja
Publication of JP2011500091A5 publication Critical patent/JP2011500091A5/ja
Application granted granted Critical
Publication of JP5808536B2 publication Critical patent/JP5808536B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—RNA viruses
    • C07K16/11—Paramyxoviridae (F); Pneumoviridae (F), e.g. respiratory syncytial virus [RSV]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/54—F(ab')2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/11011—Alpharetrovirus, e.g. avian leucosis virus

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Breeding Of Plants And Reproduction By Means Of Culturing (AREA)
JP2010531283A 2007-10-25 2008-10-24 抗ｒｓｖｇタンパク質抗体 Active JP5808536B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US46907P 2007-10-25 2007-10-25
US61/000,469 2007-10-25
US8940108P 2008-08-15 2008-08-15
US61/089,401 2008-08-15
PCT/US2008/081175 WO2009055711A2 (en) 2007-10-25 2008-10-24 Anti-rsv g protein antibodies

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2015006644A Division JP2015078231A (ja) 2007-10-25 2015-01-16 抗ｒｓｖｇタンパク質抗体

Publications (3)

Publication Number Publication Date
JP2011500091A JP2011500091A (ja) 2011-01-06
JP2011500091A5 JP2011500091A5 (https=) 2011-10-27
JP5808536B2 true JP5808536B2 (ja) 2015-11-10

Family

ID=40580419

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2010531283A Active JP5808536B2 (ja) 2007-10-25 2008-10-24 抗ｒｓｖｇタンパク質抗体
JP2015006644A Withdrawn JP2015078231A (ja) 2007-10-25 2015-01-16 抗ｒｓｖｇタンパク質抗体

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2015006644A Withdrawn JP2015078231A (ja) 2007-10-25 2015-01-16 抗ｒｓｖｇタンパク質抗体

Country Status (14)

Country Link
US (3) US7736648B2 (https=)
EP (1) EP2214711B1 (https=)
JP (2) JP5808536B2 (https=)
KR (1) KR101671452B1 (https=)
CN (1) CN101808663B (https=)
AU (1) AU2008316703B2 (https=)
BR (1) BRPI0819210A2 (https=)
CA (1) CA2703667C (https=)
IL (1) IL205257A (https=)
MX (1) MX2010004482A (https=)
NZ (1) NZ585589A (https=)
RU (1) RU2526517C2 (https=)
WO (1) WO2009055711A2 (https=)
ZA (1) ZA201003131B (https=)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003298738A1 (en) * 2002-11-26 2004-06-18 Su-Ming Chiang Liposomal formulations
WO2009055711A2 (en) * 2007-10-25 2009-04-30 Trellis Bioscience, Inc. Anti-rsv g protein antibodies
WO2013095091A2 (en) 2011-11-17 2013-06-27 Aimm Therapeutics B.V. Rsv g protein specific antibodies
US10131709B2 (en) 2011-12-28 2018-11-20 Immunoqure Ag Nucleic acid molecules encoding monoclonal antibodies specific for IL-22
WO2013098420A1 (en) * 2011-12-28 2013-07-04 Immunoqure Ag Method of isolating human antibodies
WO2013119419A1 (en) 2012-02-08 2013-08-15 North Carolina State University Treatment of allergic diseases with recombinant antibodies
TWI659968B (zh) 2013-03-14 2019-05-21 再生元醫藥公司 針對呼吸道融合病毒ｆ蛋白質的人類抗體及其使用方法
CN111303278B (zh) * 2013-04-15 2022-09-06 扬森疫苗与预防公司 结合到rsv g蛋白的人类抗体
EA035846B1 (ru) * 2013-04-15 2020-08-20 Янссен Вэксинс Энд Превеншн Б.В. Антитела человека, связывающиеся с g-белком rsv
US10196438B2 (en) 2013-04-15 2019-02-05 Janssen Vaccines & Prevention B.V. Human antibodies binding to RSV G protein
EP3105250B1 (en) * 2014-02-10 2020-08-05 IGM Biosciences, Inc. Iga multi-specific binding molecules
CN103911389A (zh) * 2014-04-09 2014-07-09 南昌大学 一种检测人呼吸道合胞病毒抗体的g和f蛋白的制备方法
BR112017011932A8 (pt) 2014-12-05 2022-11-08 Memorial Sloan Kettering Cancer Center Anticorpos direcionados a receptor acoplado a proteína g e métodos de uso
CN118271463A (zh) 2014-12-05 2024-07-02 纪念斯隆-凯特琳癌症中心 靶向g-蛋白偶联受体的嵌合抗原受体及其用途
CN106496324B (zh) * 2015-11-30 2020-01-14 天津昊免生物技术有限公司 一种抗呼吸道合胞病毒的全人源抗体
CN105542003B (zh) * 2016-03-01 2019-12-06 苏州博泰神州生物技术有限公司 一种针对rsv粘附g蛋白表面抗原的全人源单克隆抗体
WO2018089335A1 (en) 2016-11-09 2018-05-17 North Carolina State University Treatment of allergic diseases with chimeric protein
EP3573651A4 (en) 2017-01-27 2020-10-14 NGM Biopharmaceuticals, Inc. GLUCAGON RECEPTOR BINDING PROTEINS AND METHODS OF USE
CA3079604A1 (en) * 2017-10-13 2019-04-18 Trellis Bioscience, Llc Conformational epitopes in respiratory syncytial virus g protein central conserved region
US12060437B2 (en) 2018-03-23 2024-08-13 North Carolina State University Methods and compositions for antibody to high affinity receptor for IgE
EP3829636A1 (en) 2018-07-27 2021-06-09 NGM Biopharmaceuticals, Inc. Use of glucagon receptor antagonists with immunotherapeutic agent
EP3833677A4 (en) * 2018-08-08 2022-04-27 Trellis Bioscience, Inc. IMPROVED RSV PASSIVE AND ACTIVE VACCINES
EP3932424A4 (en) 2019-02-28 2022-10-12 KM Biologics Co., Ltd. Rsv f/g chimeric vaccine
WO2021046384A1 (en) 2019-09-06 2021-03-11 Silgan White Cap LLC Tethered, hinged closure
EP4031171A1 (en) * 2019-09-20 2022-07-27 Universiteit Antwerpen A novel human respiratory syncytial virus strain and its use
EP4069742A1 (en) 2019-12-06 2022-10-12 Juno Therapeutics, Inc. Anti-idiotypic antibodies to gprc5d-targeted binding domains and related compositions and methods
EP4429966A4 (en) 2021-11-08 2026-01-14 Silgan White Cap LLC PROJECTION ON THE NECK OF A CONTAINER
EP4566632A1 (en) * 2022-08-02 2025-06-11 Nona Biosciences (Suzhou) Co., Ltd. Msln antibody-drug conjugate
WO2025106427A1 (en) * 2023-11-14 2025-05-22 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Neutralizing and protective monoclonal antibodies against respiratory syncytial virus (rsv)
WO2025194126A1 (en) * 2024-03-15 2025-09-18 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Respiratory syncytial virus (rsv) g and f antibodies with high rsv-neutralizing potency

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69426077T3 (de) * 1993-05-25 2004-09-02 Wyeth Holdings Corp. Adjuvantien für impfstoffe gegen das respiratorische synzitialvirus
US6020182A (en) * 1996-07-12 2000-02-01 Connaught Laboratories Limited Subunit respiratory syncytial virus vaccine preparation
FR2766192B1 (fr) * 1997-07-17 2001-07-13 Pf Medicament Epitopes du vrs et anticorps les comportant, utiles dans le diagnostic et la therapie
US6642062B2 (en) 1998-09-03 2003-11-04 Trellis Bioinformatics, Inc. Multihued labels
US7083950B2 (en) 1998-09-25 2006-08-01 Regeneron Pharmaceuticals, Inc. High affinity fusion proteins and therapeutic and diagnostic methods for use
WO2000043040A1 (en) 1999-01-22 2000-07-27 The Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services Methods for the prevention and treatment of diseases caused by an inflammatory response mediated by endogenous substance p by using anti-substance p antibodies
CA2426312C (en) * 2000-10-18 2014-01-14 Ralph A. Tripp Compositions and methods for modulating rsv infection and immunity
US7413868B2 (en) 2003-11-05 2008-08-19 Trellis Bioscience, Inc. Use of particulate labels in bioanalyte detection methods
JP4736037B2 (ja) * 2005-10-26 2011-07-27 株式会社イーベック ヒトｇｍ−ｃｓｆに結合するヒトのモノクローナル抗体並びにその抗原結合部分
CN1986569A (zh) * 2005-12-23 2007-06-27 首都儿科研究所 人源抗呼吸道合胞病毒中和性基因工程Fab抗体
WO2007094423A1 (ja) 2006-02-15 2007-08-23 Evec Incorporated ヒトサイトメガロウイルスに結合するヒトのモノクローナル抗体並びにその抗原結合部分
WO2007101441A1 (en) * 2006-03-06 2007-09-13 Symphogen A/S Recombinant polyclonal antibody for treatment of respiratory syncytial virus infections
CA2657123A1 (en) 2006-07-12 2008-01-17 Trellis Bioscience, Inc. Cellspottm applications
WO2009055711A2 (en) * 2007-10-25 2009-04-30 Trellis Bioscience, Inc. Anti-rsv g protein antibodies

Also Published As

Publication number Publication date
KR101671452B1 (ko) 2016-11-17
WO2009055711A2 (en) 2009-04-30
CN101808663B (zh) 2015-09-30
US20100285022A1 (en) 2010-11-11
EP2214711A2 (en) 2010-08-11
KR20100091195A (ko) 2010-08-18
RU2526517C2 (ru) 2014-08-20
JP2015078231A (ja) 2015-04-23
US20130034564A1 (en) 2013-02-07
EP2214711A4 (en) 2011-12-21
US20090130120A1 (en) 2009-05-21
BRPI0819210A2 (pt) 2015-06-23
RU2010120879A (ru) 2011-11-27
AU2008316703A2 (en) 2010-07-22
AU2008316703B2 (en) 2012-09-27
MX2010004482A (es) 2010-07-06
US7736648B2 (en) 2010-06-15
AU2008316703A1 (en) 2009-04-30
JP2011500091A (ja) 2011-01-06
EP2214711B1 (en) 2018-08-15
CA2703667C (en) 2015-12-29
NZ585589A (en) 2012-07-27
US9321830B2 (en) 2016-04-26
IL205257A0 (en) 2010-12-30
CA2703667A1 (en) 2009-04-30
ZA201003131B (en) 2011-03-30
IL205257A (en) 2014-12-31
US8273354B2 (en) 2012-09-25
CN101808663A (zh) 2010-08-18
WO2009055711A3 (en) 2009-09-24

Similar Documents

Publication Publication Date Title
JP5808536B2 (ja) 抗ｒｓｖｇタンパク質抗体
US7879329B2 (en) Recombinant antibodies for treatment of respiratory syncytial virus infections
CN113943368B (zh) 一种新型冠状病毒及其突变体的单克隆抗体及其应用
CN110035771B (zh) 抗呼吸道合胞病毒抗体及其产生和使用方法
CN113929774B (zh) 一种新型冠状病毒及其突变体的单克隆抗体及其应用
US20100040606A1 (en) Recombinant polyclonal antibody for treatment of respiratory syncytial virus infections
AU2018346978A1 (en) Anti-respiratory syncytial virus antibodies, methods of their generation and use
JP2022065140A (ja) 抗呼吸器合胞体ウイルス抗体、及び、それらの生成及び使用の方法
EP2582389B1 (en) High affinity human antibodies to human cytomegalovirus (cmv) gb protein
CN114174331B (zh) 结合人类偏肺病毒融合蛋白的抗体及其用途
TW202144405A (zh) 抗新型冠狀病毒(SARS-CoV-2)之新穎單株抗體及其應用
TW202306980A (zh) 一種呼吸道融合病毒的抗體及其應用
EP1178829A1 (en) Human monoclonal antibody
Abu-Shmais et al. A potently neutralizing and protective human antibody targeting antigenic site V on RSV and hMPV fusion glycoprotein
RU2779105C2 (ru) Антитела к респираторно-синцитиальному вирусу и способы их получения и применения
CN117088971A (zh) 甲型肝炎病毒抗体及其应用
JP2011050269A (ja) 狂犬病ウイルスに対するヒト抗体ならびにその医薬組成物

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20110907

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20110907

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20130813

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20131113

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20131120

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20131128

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20131224

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20140317

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20140916

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20150116

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20150202

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20150407

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20150706

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20150908

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20150909

R150 Certificate of patent or registration of utility model

Ref document number: 5808536

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250